Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMIZE
NCT04835506Phase 4Active, not recruiting
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Nov 2021
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 4 trial of infliximab in inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis (UC), sponsored by Beth Israel Deaconess Medical Center. Started Nov 2021; status: active, not recruiting.
02
Drugs
infliximab
03
Conditions
inflammatory bowel disease (IBD)Crohn's diseaseulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04835506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04835506.